In conclusion, our study provides a possible mechanism by which IL-33 stimulates the anticancer activities of eosinophils through EV-mediated reprogramming of tumor cells and opens new perspectives on the use of eosinophil-derived EV in cancer therapy. Here, IL33 is linked to cancer.